Find policies, billing codes, payers, states, and providers
Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and limitations for serum biomarker and multianalyte panel testing used to evaluate and monitor hepatic fibrosis in individuals with chronic liver disease; it affects providers submitting claims to Oscar Health for these tests.
No material clinical or coverage changes in this revision.
Coverage Criteria for Serum and Multianalyte Fibrosis Testing
Permitted serum testing
Covered when ALL of the following are met
Supportive documentation of diagnosis or elevated liver stiffness required
Disallowed assays
Not medically necessary for other liver disease
Guideline-concordant indications and thresholds
Covered when used in accordance with guideline-recommended indications and thresholds
Recommendation I, A; use NITs to inform treatment and surveillance decisions
ELF approved as prognostic biomarker when elastography unavailable
Serial monitoring with NITs may inform management; combine serum and imaging-based NITs for improved accuracy
Clinical features of decompensated cirrhosis described in guideline
Guideline-based coverage and use criteria
Guideline-driven recommendations for use of non-invasive tests:
WHO guidance referenced (2015, updated 2024).
EASL guidance supports first-line use and describes limitations; follow-up intervals for NAFLD (e.g., reassess every 3 years) noted.
NICE recommendation for monitoring frequency.
EASL strong recommendation for primary care implementation.
Use of other multianalyte assays that rely on proprietary algorithms (for example, LIVERFASt™) is explicitly excluded and does not meet criteria for coverage in any situation described by this policy. This exclusion applies regardless of clinical indication or setting.
FibroTest™ has demonstrated variable performance in NAFLD: a meta-analysis reported a mean AUC of 0.77 with mean sensitivity 0.72 and mean specificity 0.69, and the test showed low specificity in many settings. Because of this limited specificity, FibroTest™ can generate false positives—particularly in low-prevalence primary care populations—potentially prompting unnecessary invasive or costly follow-up testing.
Non-invasive tests (serum biomarkers and transient elastography) are less well validated for some conditions: guideline statements note that NITs are better at ruling out advanced fibrosis than confirming it, and that non-invasive methods are not validated for diagnosis of NASH. The limitations of NITs versus biopsy should be recognized when applying results outside the better-studied contexts such as viral hepatitis.
The following section provides the evidence base and guideline citations referenced in this policy (refs 23–52). These references support the statements on diagnostic accuracy, guideline recommendations, and the limitations of non-invasive tests described elsewhere in this document.
For individuals with liver disease that do not meet the specified indications in this policy (MASLD/MASH, alcoholic hepatitis, or evaluation for cACLD with elevated liver stiffness), the use of ELF™, FibroTest®, HBV FibroSURE®, or HCV FibroSURE® does not meet criteria and is considered not medically necessary.
No single biomarker or multimarker score reliably achieved a predefined acceptability threshold of AUC ≥0.80 to replace liver biopsy for detection of both NASH and clinically significant fibrosis in NAFLD cohorts. While some tests reached acceptable accuracy for selected endpoints (for example, SomaSignal for advanced fibrosis), overall evidence does not support substituting biomarkers alone for histological assessment when both NASH and significant fibrosis must be detected.
Non-invasive tests have accuracy limits: guidelines emphasize that NITs are generally more reliable for excluding advanced fibrosis than confirming it, and that identification of advanced fibrosis or cirrhosis by biomarkers and/or elastography may require confirmation by liver biopsy depending on clinical context. Clinicians should interpret NIT results within guideline-recommended pathways and consider histological confirmation for diagnostic uncertainty or to guide management when necessary.
This part of the document contains only references and publication history; it does not itself make independent 'not medically necessary' determinations beyond those stated in the policy body.
Coding and Test Frequency
Provider Actions, Documentation, and Billing Guidance
Authorization and frequency for ELF™/FibroTest®
Services must meet authorization and medical necessity guidelines; for individuals with MASLD (including MASH), alcoholic hepatitis, or to rule out cACLD in those with elevated liver stiffness, ELF™ (ELFTM) or FibroTest® testing is permitted once every six months.
Use sequential or combined NITs for NAFLD staging
When staging NAFLD, use of multiple noninvasive tests or sequential testing is recommended (for example, calculate FIB-4 first and, if >1.3 or indeterminate, follow with elastography or a second serum biomarker such as ELF™ or FibroTest®). Documentation of results may be required to justify further imaging or biopsy.
Submit specific procedure codes for proprietary biomarker panels
Specific proprietary and panel biomarker tests are listed with procedure codes; when requesting coverage or submitting claims, include the specific procedure code for proprietary tests (e.g., 0166U for LiverFASt™) as indicated in the coding section.
No separate prior authorization rule specified
This section of the policy does not establish additional prior authorization requirements beyond the need for services to meet authorization and medical necessity guidelines; no separate prior authorization rule is specified here.
Stepwise testing: start with FIB-4, escalate as indicated
Follow a stepwise testing approach in clinical pathways: begin with a simple, inexpensive test (e.g., FIB-4) and proceed to more specific testing (ELF™, FibroScan, or FibroTest®) for indeterminate or high-risk results.
Preferred first-line testing: simple biomarkers or elastography
Use simple serum biomarkers (APRI, FIB-4, NFS) or elastography as first-line noninvasive tests; combine biomarker panels with elastography as needed to improve diagnostic accuracy before using proprietary multianalyte assays.
No step therapy rules provided
No step therapy rules for laboratory or imaging tests are provided in the references section of this policy.
Document indication and timing to support medical necessity
Providers must submit accurate documentation supporting medical necessity and authorization per member benefits and applicable state rules; documentation should support the indication (e.g., MASLD/MASH, alcoholic hepatitis, or elevated liver stiffness for cACLD) and timing (tests like ELF™ or FibroTest® allowed once every six months for indicated conditions).
Monitor and document routine labs every six months for cirrhosis
For patients with cirrhosis, clinicians should monitor and document a basic metabolic panel, liver function tests, complete blood count, and PT/INR every six months to allow recalculation of Child-Pugh and MELD scores.
Obtain ALT, AST and platelet count to calculate FIB-4/APRI
Ensure routine investigations include ALT, AST and platelet count so simple noninvasive scores (e.g., FIB-4) can be calculated and reported, particularly in primary care for patients at risk of liver fibrosis.
Cite guideline and evidence references (refs 23–52)
Support clinical decisions and documentation with the cited evidence-based literature and guidelines listed in the references (refs 23–52).
Adhere to coding/billing and indication rules to avoid denial
Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed; use of ELF™, FibroTest®, HBV FibroSURE®, HCV FibroSURE® or multianalyte algorithmic assays (e.g., LIVERFASt™) outside their specified indications may not meet criteria and could be disallowed.
False-positive risk with FibroTest™ may trigger unnecessary follow-up
Because FibroTest™ has low specificity in NAFLD, its use in low-prevalence primary care settings can generate false positives that lead to unnecessary invasive and expensive follow-up testing—such downstream testing may be denied if not clinically indicated.
- FibroTest mean AUC in NAFLD meta-analysis was 0.77 with mean specificity ~0.69.
- Low specificity can produce false positives and increased downstream testing.
Government coverage rules supersede policy and may cause denial
If this policy conflicts with an applicable government policy (e.g., Medicare LCDs/NCDs or state Medicaid), the government policy will govern the determination and may result in denial if the government policy excludes coverage.
References/publication history only — no added authorization rules
This portion of the document contains references and publication history only and does not provide additional authorization or denial criteria.
Background and Scope
Chronic liver disease (CLD) includes chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatic fibrosis reflects extracellular matrix deposition and remodeling and is a central process across these conditions. Serum biomarkers—both direct and indirect—and composite panels are used to estimate fibrosis stage noninvasively, but liver biopsy remains the reference standard with recognized sampling variability and procedural risks. Non-invasive tests can aid risk stratification and monitoring but have known limitations in specificity and in diagnosing NASH; guideline-directed use and confirmatory testing are advised where appropriate.
Key Test and Term Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.